Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-944 as a Single Agent or in Combination With ARPIs in Metastatic Prostate Cancer
NCT05413421Phase 1Recruiting
- Sponsor
- ORIC Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of rinzimetostat in prostate cancer (PCa) (3 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 12 months, Maximum plasma concentration at 28 days and 3 more. Started Jun 2022; status: recruiting.
02
Drugs
rinzimetostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05413421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413421.